Theravance Biopharma (TBPH) Misses Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Theravance Biopharma (TBPH) Will Make VIBATIV Poster Presentation at ATS 2016
May 11, 2016 8:06 AM EDTTheravance Biopharma, Inc. (NASDAQ: TBPH) announced that new data on VIBATIV (telavancin), the Company's FDA-approved antibiotic, will be the focus of a poster presentation at the American Thoracic Society (ATS) 2016 International Conference. Researchers will present results from post hoc analyses of the previously completed Phase 3 ATTAIN (Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia) studies, registrational trials which supported the regulatory approval of telavancin (marketed as VIBATIV) for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). The ATS 2016 International Conference is being held in San Francisco on May 13-18, 2016.
The... More
